The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Nintedanib: From Discovery to the Clinic
Open accessAbstract
Nintedanib (BIBF1120) is a potent, oral, small-molecule tyrosine kinase inhibitor, also known as a triple angiokinase inhibitor, inhibiting three major signaling pathways involved in angiogenesis. Nintedanib targets proangiogenic and pro-fibrotic pathways mediated by the VEGFR family, the fibroblast growth factor receptor (FGFR) family, the platelet-derived growth factor receptor (PDGFR) family, as well as Src and Flt-3 kinases. The compound was identified during a lead optimization program for small-molecule inhibitors of angiogenesis and has since undergone extensive clinical investigation for the treatment of various solid tumors, and in patients with the debilitating lung disease idiopathic pulmonary fibrosis (IPF). Recent clinical evidence from phase III studies has shown that nintedanib has significant efficacy in the treatment of NSCLC, ovarian cancer, and IPF. This review article provides a comprehensive summary of the preclinical and clinical research and development of nintedanib from the initial drug discovery process to the latest available clinical trial data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
Self-citationReck, M., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70586-2 · Cited by 951
Self-citationThe Impact of TGF-β on Lung Fibrosis: From Targeting to Biomarkers
Fernandez, I. E., & Eickelberg, O. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201203-023aw · Cited by 679
Wollin, L., Maillet, I., Quesniaux, V., Holweg, A., & Ryffel, B. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.208223 · Cited by 633
Targeting the PDGF signaling pathway in tumor treatment
Heldin, C.-H. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-97 · Cited by 540
Demedts, M., & Costabel, U. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00492002 · Cited by 460
The Role of Fibroblast Growth Factors in Tumor Growth
Korc, M., & Friesel, R. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909789057006 · Cited by 355
Soria, J.-C., Mauguen, A., Reck, M., Sandler, A. B., Saijo, N., Johnson, D. H., Burcoveanu, D., Fukuoka, M., Besse, B., & Pignon, J.-P. (2013) · Annals of Oncology · doi:10.1093/annonc/mds590 · Cited by 314
Pathways mediating VEGF-independent tumor angiogenesis
Ferrara, N. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.003 · Cited by 313
Biomarkers to predict the clinical efficacy of bevacizumab in cancer
Jubb, A. M., & Harris, A. L. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70232-1 · Cited by 295
Lindner, V, Majack, R. A., & Reidy, M. A. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114665 · Cited by 278
Roth, G. J., Heckel, A., Colbatzky, F., Handschuh, S., Kley, J., Lehmann-Lintz, T., Lotz, R., Tontsch-Grunt, U., Walter, R., & Hilberg, F. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900431g · Cited by 237
Self-citationLedermann, J. A., Hackshaw, A. K., Kaye, S. B., Jayson, G. C., Gabra, H., McNeish, I. A., Earl, H. M., Perren, T. J., Gore, M. E., Persic, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5208 · Cited by 217
Vascular endothelial growth factor up‐regulation and bronchial wall remodelling in asthma
Chetta, A., Zanini, A., Foresi, A., D'Ippolito, R., Tipa, A., Castagnaro, A., Baraldo, S., Neri, M., Saetta, M., & Olivieri, D. (2005) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2005.02360.x · Cited by 197
Hetzel, M., Bachem, M., Anders, D., Trischler, G., & Faehling, M. (2005) · Lung · doi:10.1007/s00408-004-2534-z · Cited by 186
Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors
Mross, K., Stefanic, M., Gmehling, D., Frost, A., Baas, F., Unger, C., Strecker, R., Henning, J., Gaschler-Markefski, B., Stopfer, P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0694 · Cited by 171
Self-citationAnti-Vascular Endothelial Growth Factor Gene Therapy Attenuates Lung Injury and Fibrosis in Mice
Hamada, N., Kuwano, K., Yamada, M., Hagimoto, N., Hiasa, K., Egashira, K., Nakashima, N., Maeyama, T., Yoshimi, M., & Nakanishi, Y. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.2.1224 · Cited by 170
Reck, M., Kaiser, R., Eschbach, C., Štefanič, M., Love, J., Gatzemeier, U., Stopfer, P., & von Pawel, J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq618 · Cited by 152
Self-citationKindler, H. L., & Shulman, K. L. (2001) · Current Treatment Options in Oncology · doi:10.1007/s11864-001-0068-7 · Cited by 133
Inoue, Y., King, T. E., Barker, E. P., Daniloff, E., & Newman, L. S. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2010014 · Cited by 130
Berger, W., Setinek, U., Mohr, T. T., Kindås-Mügge, I., Vetterlein, M., Dekan, G., Eckersberger, F., Caldas, C. H., & Micksche, M. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991029)83:3<415::aid-ijc19>3.0.co;2-y · Cited by 115
Biomarkers in idiopathic pulmonary fibrosis
Zhang, Y., & Kaminski, N. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328356d03c · Cited by 113
Ellis, P. M., Kaiser, R., Zhao, Y., Stopfer, P., Gyorffy, S., & Hanna, N. H. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2944 · Cited by 98
Self-citationOkamoto, I., Kaneda, H., Satoh, T., Okamoto, W., Miyazaki, M., Morinaga, R., Ueda, S., Terashima, M., Tsuya, A., Sarashina, A., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0379 · Cited by 94
Self-citationHanna, N. H., Kaiser, R., Sullivan, R. N., Aren, O. R., Ahn, M., Tiangco, B., Zvirbule, Z., Barrios, C. H., Demirkazık, A., Gaschler‐Markefski, B., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8034 · Cited by 83
Self-citationPharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers
Stopfer, P., Rathgen, K., Bischoff, D., Lüdtke, S., Marzin, K., Kaiser, R., Wagner, K., & Ebner, T. (2011) · Xenobiotica · doi:10.3109/00498254.2010.545452 · Cited by 80
Self-citationDoebele, R. C., Conkling, P., Traynor, A. M., Otterson, G. A., Zhao, Y., Wind, S., Stopfer, P., Kaiser, R., & Camidge, D. R. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr596 · Cited by 79
Self-citationHo, H. K., Yeo, A. H. L., Kang, T. S., & Chua, B. T. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.021 · Cited by 66
du Bois, A., Huober, J., Stopfer, P., Pfisterer, J., Wimberger, P., Loibl, S., Reichardt, V. L., & Harter, P. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp506 · Cited by 62
Eisen, T. G., Shparyk, Y. V., MacLeod, N. J., Jones, R. J., Wallenstein, G., Temple, G., Khder, Y., Dallinger, C., Studeny, M., Loembé, A., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9962-7 · Cited by 53
Self-citationBousquet, G., Alexandre, J., Tourneau, C. L., Goldwasser, F., Faivre, S. J., de Mont-Serrat, H., Kaiser, R., Misset, J. L., & Raymond, É. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.440 · Cited by 47
Self-citationYu, Z.-H., Wang, D., Zhou, Z.-Y., He, S.-L., Chen, A., & Wang, J. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.35.731 · Cited by 31
Hilberg, F., & Brandstetter, I. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000283231.76336.01 · Cited by 18
Self-citationStopfer, P., Roth, W., Mross, K. B., Judson, I. R., Kienast, J., Kaiser, R., & Štefanič, M. (2006) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(06)70079-9 · Cited by 17
Self-citation
Cited by
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
Shared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
Defining the Activated Fibroblast Population in Lung Fibrosis Using Single-Cell Sequencing
Peyser, R., MacDonnell, S., Gao, Y., Cheng, L., Kim, Y., Kaplan, T., Ruan, Q., Wei, Y., Ni, M., Adler, C., et al. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0313oc · Cited by 210
Metadata
- Authors
- Roth, G. J., Binder, R., Colbatzky, F., Dallinger, C., Schlenker-Herceg, R., Hilberg, F., Wollin, S.-L., & Kaiser, R.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-01-14
- Volume
- 58
- Issue
- 3
- Pages
- 1053-1063
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2014689880
- Cited by
- 335
- References
- 39
- Type
- other
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.